Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Medpace Holdings Inc’s stock clocked out at $308.88, down -0.96% from its previous closing price of $311.87. In other words, the price has decreased by -$0.96 from its previous closing price. On the day, 0.99 million shares were traded. MEDP stock price reached its highest trading level at $316.405 during the session, while it also had its lowest trading level at $306.7035.
Ratios:
To gain a deeper understanding of MEDP’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 20.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.41. For the most recent quarter (mrq), Quick Ratio is recorded 0.73 and its Current Ratio is at 0.73. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.21.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on June 24, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $300.
TD Cowen Downgraded its Buy to Hold on April 14, 2025, while the target price for the stock was maintained at $328.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 24 ’25 when DAVENPORT FRED B JR sold 1,712 shares for $301.82 per share. The transaction valued at 516,716 led to the insider holds 2,998 shares of the business.
DAVENPORT FRED B JR bought 1,712 shares of MEDP for $516,716 on Apr 24 ’25. On Feb 27 ’25, another insider, EWALD STEPHEN P, who serves as the General Counsel & Corp. Secy. of the company, bought 2 shares for $326.11 each. As a result, the insider paid 652 and bolstered with 13,343 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MEDP now has a Market Capitalization of 8877705216 and an Enterprise Value of 8729754624. As of this moment, Medpace’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.57, and their Forward P/E ratio for the next fiscal year is 23.55. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.12 while its Price-to-Book (P/B) ratio in mrq is 15.49. Its current Enterprise Value per Revenue stands at 4.048 whereas that against EBITDA is 17.98.
Stock Price History:
The Beta on a monthly basis for MEDP is 1.40, which has changed by -0.28663254 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, MEDP has reached a high of $440.38, while it has fallen to a 52-week low of $250.05. The 50-Day Moving Average of the stock is 0.56%, while the 200-Day Moving Average is calculated to be -4.92%.
Shares Statistics:
It appears that MEDP traded 431.90K shares on average per day over the past three months and 348750 shares per day over the past ten days. A total of 29.77M shares are outstanding, with a floating share count of 23.17M. Insiders hold about 19.38% of the company’s shares, while institutions hold 90.63% stake in the company. Shares short for MEDP as of 1749772800 were 3094745 with a Short Ratio of 7.56, compared to 1747267200 on 2895416. Therefore, it implies a Short% of Shares Outstanding of 3094745 and a Short% of Float of 13.55.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Medpace Holdings Inc (MEDP) is currently in the spotlight, with 6.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $3.05, with high estimates of $3.29 and low estimates of $2.94.
Analysts are recommending an EPS of between $14.01 and $12.45 for the fiscal current year, implying an average EPS of $12.94. EPS for the following year is $13.44, with 8.0 analysts recommending between $14.81 and $12.45.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $537.98M. It ranges from a high estimate of $547.8M to a low estimate of $522M. As of the current estimate, Medpace Holdings Inc’s year-ago sales were $528.1MFor the next quarter, 9 analysts are estimating revenue of $543.21M. There is a high estimate of $561.72M for the next quarter, whereas the lowest estimate is $527.3M.
A total of 11 analysts have provided revenue estimates for MEDP’s current fiscal year. The highest revenue estimate was $2.23B, while the lowest revenue estimate was $2.14B, resulting in an average revenue estimate of $2.18B. In the same quarter a year ago, actual revenue was $2.11BBased on 12 analysts’ estimates, the company’s revenue will be $2.28B in the next fiscal year. The high estimate is $2.56B and the low estimate is $2.19B.
